# UiPath, Inc.: financial statements, quarterly

PATH · NYSE · CIK 1734722 · [Technology](/sectors/technology.md) · fiscal year ends Jan 31

Pages: [Overview](/companies/path.md) · [Financials](/companies/path/financials.md) · [Filings](/companies/path/filings.md) · [Insiders](/companies/path/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/path/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [326](/filings/0001734722-24-000059.md) | [405 d](/filings/0001734722-26-000012.md) | [335](/filings/0001734722-25-000030.md) | [316](/filings/0001734722-25-000043.md) | [355](/filings/0001734722-25-000050.md) | [424 d](/filings/0001734722-26-000012.md) | [357](/filings/0001734722-26-000041.md) | [362](/filings/0001734722-26-000050.md) | [411](/filings/0001734722-25-000050.md) | [481 d](/filings/0001734722-26-000012.md) | [418](/filings/0001734722-26-000041.md) | [410](/filings/0001734722-26-000050.md) |
| Cost of revenue | $m | [49.9](/filings/0001734722-24-000059.md) | [53.4 d](/filings/0001734722-26-000012.md) | [55.3](/filings/0001734722-25-000030.md) | [63.3](/filings/0001734722-25-000043.md) | [63.8](/filings/0001734722-25-000050.md) | [64.5 d](/filings/0001734722-26-000012.md) | [63.9](/filings/0001734722-26-000041.md) | [64.4](/filings/0001734722-26-000050.md) | [68.8](/filings/0001734722-25-000050.md) | [73.9 d](/filings/0001734722-26-000012.md) | [76.9](/filings/0001734722-26-000041.md) | [80.6](/filings/0001734722-26-000050.md) |
| Gross profit | $m | [276](/filings/0001734722-24-000059.md) | [352 d](/filings/0001734722-26-000012.md) | [280](/filings/0001734722-25-000030.md) | [253](/filings/0001734722-25-000043.md) | [291](/filings/0001734722-25-000050.md) | [359 d](/filings/0001734722-26-000012.md) | [293](/filings/0001734722-26-000041.md) | [297](/filings/0001734722-26-000050.md) | [342](/filings/0001734722-25-000050.md) | [407 d](/filings/0001734722-26-000012.md) | [341](/filings/0001734722-26-000041.md) | [330](/filings/0001734722-26-000050.md) |
| Research and development | $m | [84.5](/filings/0001734722-24-000059.md) | [85.6 d](/filings/0001734722-26-000012.md) | [85.6](/filings/0001734722-25-000030.md) | [98.4](/filings/0001734722-25-000043.md) | [97.0](/filings/0001734722-25-000050.md) | [99.7 d](/filings/0001734722-26-000012.md) | [94.8](/filings/0001734722-26-000041.md) | [98.3](/filings/0001734722-26-000050.md) | [96.9](/filings/0001734722-25-000050.md) | [95.2 d](/filings/0001734722-26-000012.md) | [92.9](/filings/0001734722-26-000041.md) | [83.4](/filings/0001734722-26-000050.md) |
| Operating income | $m | [(55.8)](/filings/0001734722-24-000059.md) | [15.1 d](/filings/0001734722-26-000012.md) | [(49.5)](/filings/0001734722-25-000030.md) | [(103)](/filings/0001734722-25-000043.md) | [(43.4)](/filings/0001734722-25-000050.md) | [33.6 d](/filings/0001734722-26-000012.md) | [(16.4)](/filings/0001734722-26-000041.md) | [(20.2)](/filings/0001734722-26-000050.md) | [13.1](/filings/0001734722-25-000050.md) | [80.3 d](/filings/0001734722-26-000012.md) | [28.0](/filings/0001734722-26-000041.md) | [31.6](/filings/0001734722-26-000050.md) |
| Income tax | $m | [3.9](/filings/0001734722-24-000059.md) | [2.7 d](/filings/0001734722-26-000012.md) | [3.8](/filings/0001734722-25-000030.md) | [3.8](/filings/0001734722-25-000043.md) | [(14.8)](/filings/0001734722-25-000050.md) | [2.8 d](/filings/0001734722-26-000012.md) | [2.8](/filings/0001734722-26-000041.md) | [1.7](/filings/0001734722-26-000050.md) | [(174)](/filings/0001734722-25-000050.md) | [(12.0) d](/filings/0001734722-26-000012.md) | [18.4](/filings/0001734722-26-000041.md) | [16.8](/filings/0001734722-26-000050.md) |
| Net income | $m | [(31.5)](/filings/0001734722-24-000059.md) | [33.9 d](/filings/0001734722-26-000012.md) | [(28.7)](/filings/0001734722-25-000050.md) | [(86.1)](/filings/0001734722-25-000050.md) | [(10.7)](/filings/0001734722-25-000050.md) | [51.8 d](/filings/0001734722-26-000012.md) | [(22.6)](/filings/0001734722-26-000050.md) | [1.6](/filings/0001734722-26-000050.md) | [199](/filings/0001734722-25-000050.md) | [104 d](/filings/0001734722-26-000012.md) | [22.5](/filings/0001734722-26-000050.md) | [36.1](/filings/0001734722-26-000050.md) |
| Diluted EPS | $ per share | [(0.06)](/filings/0001734722-24-000059.md) | not reported | [(0.05)](/filings/0001734722-25-000030.md) | [(0.15)](/filings/0001734722-25-000043.md) | [(0.02)](/filings/0001734722-25-000050.md) | not reported | [(0.04)](/filings/0001734722-26-000041.md) | [0.00](/filings/0001734722-26-000050.md) | [0.37](/filings/0001734722-25-000050.md) | not reported | [0.04](/filings/0001734722-26-000041.md) | [0.07](/filings/0001734722-26-000050.md) |
| Basic EPS | $ per share | [(0.06)](/filings/0001734722-24-000059.md) | not reported | [(0.05)](/filings/0001734722-25-000030.md) | [(0.15)](/filings/0001734722-25-000043.md) | [(0.02)](/filings/0001734722-25-000050.md) | not reported | [(0.04)](/filings/0001734722-26-000041.md) | [0.00](/filings/0001734722-26-000050.md) | [0.37](/filings/0001734722-25-000050.md) | not reported | [0.04](/filings/0001734722-26-000041.md) | [0.07](/filings/0001734722-26-000050.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2024 (2023-10-31) | FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [1,003](/filings/0001734722-23-000065.md) | [1,062](/filings/0001734722-25-000007.md) | [1,147](/filings/0001734722-24-000039.md) | [939](/filings/0001734722-24-000051.md) | [774](/filings/0001734722-24-000059.md) | [879](/filings/0001734722-26-000012.md) | [701](/filings/0001734722-25-000030.md) | [629](/filings/0001734722-25-000043.md) | [744](/filings/0001734722-25-000050.md) | [871](/filings/0001734722-26-000050.md) | [632](/filings/0001734722-26-000041.md) | [607](/filings/0001734722-26-000050.md) |
| Current assets | $m | [2,430](/filings/0001734722-23-000065.md) | [2,580](/filings/0001734722-25-000007.md) | [2,469](/filings/0001734722-24-000039.md) | [2,274](/filings/0001734722-24-000051.md) | [2,176](/filings/0001734722-24-000059.md) | [2,339](/filings/0001734722-26-000012.md) | [2,110](/filings/0001734722-25-000030.md) | [2,031](/filings/0001734722-25-000043.md) | [2,093](/filings/0001734722-25-000050.md) | [2,244](/filings/0001734722-26-000050.md) | [1,918](/filings/0001734722-26-000041.md) | [1,927](/filings/0001734722-26-000050.md) |
| Total assets | $m | [2,787](/filings/0001734722-23-000065.md) | [2,955](/filings/0001734722-25-000007.md) | [2,845](/filings/0001734722-24-000039.md) | [2,701](/filings/0001734722-24-000051.md) | [2,663](/filings/0001734722-24-000059.md) | [2,865](/filings/0001734722-26-000012.md) | [2,644](/filings/0001734722-25-000030.md) | [2,592](/filings/0001734722-25-000043.md) | [2,896](/filings/0001734722-25-000050.md) | [3,179](/filings/0001734722-26-000050.md) | [2,905](/filings/0001734722-26-000041.md) | [2,907](/filings/0001734722-26-000050.md) |
| Current liabilities | $m | [628](/filings/0001734722-23-000065.md) | [712](/filings/0001734722-25-000007.md) | [598](/filings/0001734722-24-000039.md) | [633](/filings/0001734722-24-000051.md) | [695](/filings/0001734722-24-000059.md) | [799](/filings/0001734722-26-000012.md) | [716](/filings/0001734722-25-000030.md) | [738](/filings/0001734722-25-000043.md) | [789](/filings/0001734722-25-000050.md) | [905](/filings/0001734722-26-000050.md) | [832](/filings/0001734722-26-000041.md) | [807](/filings/0001734722-26-000050.md) |
| Total liabilities | $m | [826](/filings/0001734722-23-000065.md) | [939](/filings/0001734722-25-000007.md) | [818](/filings/0001734722-24-000039.md) | [868](/filings/0001734722-24-000051.md) | [931](/filings/0001734722-24-000059.md) | [1,020](/filings/0001734722-26-000012.md) | [946](/filings/0001734722-25-000030.md) | [927](/filings/0001734722-25-000043.md) | [971](/filings/0001734722-25-000050.md) | [1,097](/filings/0001734722-26-000050.md) | [1,002](/filings/0001734722-26-000041.md) | [959](/filings/0001734722-26-000050.md) |
| Shareholders' equity | $m | [1,961](/filings/0001734722-24-000059.md) | [2,016](/filings/0001734722-26-000012.md) | [2,027](/filings/0001734722-25-000050.md) | [1,834](/filings/0001734722-25-000050.md) | [1,732](/filings/0001734722-25-000050.md) | [1,846](/filings/0001734722-26-000050.md) | [1,698](/filings/0001734722-26-000050.md) | [1,666](/filings/0001734722-26-000050.md) | [1,925](/filings/0001734722-25-000050.md) | [2,083](/filings/0001734722-26-000050.md) | [1,903](/filings/0001734722-26-000050.md) | [1,949](/filings/0001734722-26-000050.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [41.9 d](/filings/0001734722-24-000059.md) | [146 d](/filings/0001734722-26-000012.md) | [100](/filings/0001734722-25-000030.md) | [46.4 d](/filings/0001734722-25-000043.md) | [28.1 d](/filings/0001734722-25-000050.md) | [146 d](/filings/0001734722-26-000012.md) | [119](/filings/0001734722-26-000041.md) | [41.6 d](/filings/0001734722-26-000050.md) | [28.3 d](/filings/0001734722-25-000050.md) | [182 d](/filings/0001734722-26-000012.md) | [132](/filings/0001734722-26-000041.md) | [30.7 d](/filings/0001734722-26-000050.md) |
| Capital expenditure | $m | [0.7 d](/filings/0001734722-24-000059.md) | [3.8 d](/filings/0001734722-26-000012.md) | [1.2](/filings/0001734722-25-000030.md) | [1.4 d](/filings/0001734722-25-000043.md) | [4.9 d](/filings/0001734722-25-000050.md) | [7.4 d](/filings/0001734722-26-000012.md) | [12.8](/filings/0001734722-26-000041.md) | [0.0 d](/filings/0001734722-26-000050.md) | [3.2 d](/filings/0001734722-25-000050.md) | [3.1 d](/filings/0001734722-26-000012.md) | [2.7](/filings/0001734722-26-000041.md) | [1.4 d](/filings/0001734722-26-000050.md) |
| Share repurchases | $m | [52.6 d](/filings/0001734722-24-000059.md) | [50.0 d](/filings/0001734722-26-000012.md) | [22.0](/filings/0001734722-25-000030.md) | [197 d](/filings/0001734722-25-000043.md) | [163 d](/filings/0001734722-25-000050.md) | [9.3 d](/filings/0001734722-26-000012.md) | [228](/filings/0001734722-26-000041.md) | [102 d](/filings/0001734722-26-000050.md) | [0.0 d](/filings/0001734722-25-000050.md) | [0.0 d](/filings/0001734722-26-000012.md) | [244](/filings/0001734722-26-000041.md) | [24.8 d](/filings/0001734722-26-000050.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2023 (2022-10-31) | Q1 FY2024 (2023-04-30) | Q2 FY2024 (2023-07-31) | Q3 FY2024 (2023-10-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [550](/filings/0001734722-23-000065.md) | [558](/filings/0001734722-24-000039.md) | [563](/filings/0001734722-24-000051.md) | [567](/filings/0001734722-24-000059.md) | [570](/filings/0001734722-25-000030.md) | [568](/filings/0001734722-25-000043.md) | [551](/filings/0001734722-25-000050.md) | [548](/filings/0001734722-26-000041.md) | [543](/filings/0001734722-26-000050.md) | [539](/filings/0001734722-25-000050.md) | [528](/filings/0001734722-26-000041.md) | [523](/filings/0001734722-26-000050.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.